Wednesday 23rd September Patient Event from 10.00, in person only, at Homerton College, Cambridge The day will start with a “Living Well With Vasculitis” event, from 10am. Jane Hollis, a …
Avacopan (Tavneos): MHRA Decision and UK Withdrawal Plan
1st September 2026 Summary The Medicines and Healthcare products Regulatory Agency (MHRA) has completed its review of Avacopan Vifor (previously Tavneos) and concluded that the evidence supporting its efficacy is …
Avacopan (Tavneos): Regulatory Update and UK Position – August 2026
The European Commission has now formally revoked the EU marketing authorisation for Tavneos (avacopan), following the recommendation of the European Medicines Agency (EMA). This decision was made under Article 116 …
Upadacitinib (Rinvoq®) accepted for restricted use within NHS Scotland.
The Scottish Medicines Consortium (SMC) has accepted upadacitinib for use to treat adults with giant cell arteritis. SMC has accepted upadacitinib for restricted use. The restriction means upadacitinib can be …
Tavneos update (June 2026)
Today, 26th June, the European Medicines Agency (EMA) issued a recommendation to revoke the marketing authorisation for Tavneos (avacopan) in the European Union. This decision does not apply to the …
Avacopan update
On 5th June 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) announced that they are starting a review of the ‘benefits and risks of avacopan’. (Statement here). Whilst …
Introducing “See Me Hear Me”:
A website to support people affected by ANCA-Associated Vasculitis We are delighted to announce the launch of See Me Hear Me, a dedicated UK websitedesigned to support people living with …
Tavneos (avacopan) – update
Vasculitis International have issued an important update about investigation into Tavneos (avacopan) by the USA regulator the FDA. Patients on this drug should read the update to understand the situation …
Patient Day and AGM 2026
Vasculitis UK will be holding a Patient Day, along with our 2026 AGM on Wednesday 23rd September in Cambridge, UK. More details to follow.
EMA Review of Tavneos® (avacopan)
The European Medicines Agency (EMA) has started a review of Tavneos® (avacopan), a medicine used to treat ANCA-associated vasculitis, including GPA and MPA. This review is not due to new safety concerns or side …